Risk factors of hepatitis B in patients on hemodialysis: a systematic review
https://doi.org/10.23946/2500-0764-2019-4-2-107-119
Abstract
Aim. To perform a systematic review of hepatitis В risk factors in patients receiving hemodialysis.
Materials and Methods. We screened English-and Russian-language databases for relevant obser- vational cohort studies. Screening of publications and extraction of primary data were carried out in accordance with the Cochrane recommendations. The significance of hepatitis В risk factors was given in odds ratios with 95% confidence intervals.
Results. All included primary studies demonstrated that patients on hemodialysis are at high risk of acquiring blood-borne diseases due to the combination of various risk factors. For example, duration of hemodialysis > 2 years significantly increased hepatitis В risk (OR = 2.24, 1QR 1.052.08).
Conclusion. A critical attitude to modifiable and non-modifiable risk factors increases the effectiveness of epidemiological surveillance and infection control and ensures quality and safety of medical care for the patients receiving hemodialysis.
About the Authors
D. V. Kvashnina
PrivoIzhskiy Research Medical University
Russian Federation
Russian Federation
Dr. Daria V. Kvashnina - MD, PhD, Senior Lecturer, Department ofEpidemiology, Microbiology and Evidence-Based medicine.
70, Gagarina Prospekt, N. Novgorod, 603081
O. V. Kovalishena
PrivoIzhskiy Research Medical University
Russian Federation
Russian Federation
Prof. Olga V. Kovalishena - MD, DSc, Head ofthe Department ofEpidemiology, Microbiology and Evidence-Based medicine.
10/1, Minin and Pozharsky Square, Nizhniy Novgorod, 603005
N. V. Saperkin
Utrecht University
Netherlands
Netherlands
Dr. Nikolay V. Saperkin - MD, PhD, Researcher.
Domplein 29, 3512 JE, Utrecht
References
1. Nephrology. Clinical guidelines / Shilova EM, Smirnova AV, Kozlovskaya NL [Ed]. Moscow: GEOTAR-Media, 2016. 816 p. Russian
2. Chronic kidney disease: Selected chapters of nephrology. Tomilina NA. Moscow: GEOTAR-Media, 2017. 512 p. Russian
3. Tomilina NA, Andrusev AM, Peregudova NG, Shinkarev MB. Renal replacement therapy for End Stage Renal Disease in Russian Federation, 2010-2015. Russian National Renal Replacement Therapy Registry Report of Russian Public Organization of Nephrologists "Russian Dialysis Society", Part 1. Nephrology and Dialysis. 2017. 19 (4): 1-95. Russian
4. Rinonce НТ, Yano Y, Utsumi Т, Heriyanto DS, Anggorowati N, Widasari DI, et al. Hepatitis В and C virus infection among hemodialysis patients in Yogyakarta, Indonesia: Prevalence and molecular evidence for nosocomial transmission. J Med Virol. 2013; 85 (8): 1348-1361.
5. Bohlke M, Uliano G, Barcellos FC. Hemodialysis catheter-related infection: prophylaxis, diagnosis and treatment. J Vase Access. 2015; 16 (5): 347-355. doi: 10.5301/jva.5000368.
6. Gallieni M, Brenna I, Brunini F, Mezzina N, Pasho S, Giordano A. Dialysis central venous catheter types and performance. J Vase Access. 2014; 15 (Suppl 7): 140-146. doi: 10.5301/jva.5000262.
7. Murea M, James KM, Russell GB, Byrum GV, Yates JE, Tuttle NS, et al. Risk of catheter-related bloodstream infection in elderly patients on hemodialysis. Clin J Am Soc Nephrol. 2014; 9 (4): 764-770. doi: 10.2215/CJN.07710713.
8. Keyvani H, Agah S, Kabir A, Alavian SM. Prevalence and risk factors of isolated anti-HBc antibody and occult hepatitis В infection in hemodialysis patients: a nationwide study. Ann Hepatol. 2013; 12(2): 213-219.
9. Bernieh B. Viral hepatitis in hemodialysis: An update. J Transl Int Med. 2015; 3 (3): 93-105. doi: 10.1515/jtim-2015-0018.
10. Eleftheriadis T, Pissas G, Antoniadi G, Liakopoulos V, Stefanidis I. Factors affecting effectiveness of vaccination against hepatitis В virus in hemodialysis patients. World J Gastroenterol. 2014; 20 (34): 12018-12025. doi: 10.3748/wjg.v20.i34.12018.
11. Djalalinia S, Ramezan Ghorbani N, Tajbakhsh R, Modirian M, Esmaeili Abdar Z, Mahdavi Gorabi A, et al. Hepatitis В Virus Infection in Iranian Hemodialysis Patients: a Systematic Review and Meta-Analysis. Iran J Kidney Dis. 2018; 12 (1): 1-9.
12. Li M, Wang P, Yang C, Jiang W, Wei X, Mu X, et al. A systematic review and meta-analysis: Does hepatitis C virus infection predispose to the development of chronic kidney disease? Oncotarget. 2017; 8 (6): 10692-10702. doi: 10.18632/oncotarget.12896.
13. Fabrizi F, Donato FM, Messa P. Association between hepatitis B virus and chronic kidney disease: a systematic review and meta-analysis. Ann Hepatol. 2017; 16 (1): 21-47. doi: 10.5604/16652681.1226813.
14. Cai QC, Zhao SQ, Shi TD, Ren H. Relationship between hepatitis B virus infection and chronic kidney disease in Asian populations: a meta-analysis. Ren Fail. 2016; 38 (10): 15811588. doi: 10.1080/0886022X.2016.1229548.
15. Chavez-Gomez NL, Cabello-Lopez A, Gopar-Nieto R. Aguilar-Madrid G, Marin-Lopez KS, Aceves-Valdez M, et al. Chronic kidney disease in Mexico and its relation with heavy metals. Rev Med Inst Mex Seguro Soc. 2017; 55 (6): 725-734.
16. Mikolajczyk, AE, Aronsohn, Al. Current Management of Chronic Hepatitis В and C in Chronic Kidney Disease. Adv Chronic Kidney Dis. 2015; 22 (5): 352-360. doi: 10.1053/j.ackd.2015.06.008.
17. Zueva LP, Rahmanova AG, Kolosovskaya EN, Kalinina ZP, Petrova OE, Dmitrieva MI. Epidemiological evaluation of the prevalence of viral hepatitis B and C in the staff and inpatients in hospitals of St. Petersburg. Epidemiology and Infectious Diseases. 2012; (2): 41-45. Russian
18. Mukomolov SL, Levakova IA, Sinaiskaya EV, Suliagina LG, Kisliy PN, Timakhovskaya GJ, et al. Epidemiological characteristic of viral hepatitis B and C in the hemodialysis units in Saint-Petersburg in modern time. Part 1. Registration of hemo-contact viral hepatitis and serological markers of HBV and HCV infections in patients of hemodialysis unit. Russian Journal of Infection and Immunity. 2011; 1(2): 143150. Russian doi: 10.15789/2220-7619-2011-2-143-150.
19. Fabrizi F, Dixit V, Messa P, Martin P. Transmission of hepatitis B virus in dialysis units: a systematic review of reports on outbreaks. Int J Artif Organs. 2015; 38 (1): 1-7. doi: 10.5301/ijao.5000376.
20. Feng Y, Shi X, Shi J, Gao L, Liu G, Cheng Y, et al. Immunogenicity, antibody persistence, and safety of the 60 pg hepatitis В vaccine in hemodialysis patients: a multicenter, randomized, double-blind, parallel-controlled trial. Expert Rev Vaccines. 2017; 16 (10). 1045-1052. doi: 10.1080/14760584.2017.1367667.
21. Cordova E, Miglia I, Festuccia F, Sarlo MG. Scornavacca G, Punzo G, et al. Hepatitis В vaccination in haemodialysis patients: an underestimated problem. Factors influencing immune responses in ten years of observation in an Italian haemodialysis centre and literature review. Ann Ig. 2017; 29 (1): 27-37. doi: 10.7416/ai.2017.2129.
22. Al Saran K, Sabry A, Al Halawany Z, Ismail M. Factors affecting response to hepatitis B vaccine among hemodialysis patients in a large Saudi Hemodialysis Center. Saudi J Kidney Dis Transpl. 2014; 25 (1): 185-191.
23. Kostinov MP, Tarasova AA. Vaccination of children with chronic kidney disease. Epidemiology and Vaccinal Prevention. 2014; 3 (76): 109-111. Russian
24. Chingayeva GN, Abeuova BA, Naushabayeva A, Kabulbayev KA. Immune status peculiarities in pediatric hemodialysis patients prior to and after vaccination againts hepatitis B. International Journal of Applied and Fundamental Research. 2013; (5): 52-55. Russian
25. Dostiev UA, Dostiev AR, Karimov AM. Immune dysfunction in patients with end-stage chronic renal failure. Transplantology. 2016; (4): 58-62. Russian
26. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). Higgins JP, Green S, editor(s). The Cochrane Collaboration, 2011. Accessed: https://training.cochrane.org/handbook.
27. Rebrova OYu, Fedyaeva VK. The Questionnaire to Assess the Risk of Systematic Bias in Non-Randomized Comparative Studies: the Russian-Language Version of the Newcastle-Ottawa Scale. Medical technology. Evaluation and Selection. 2016; (3 (25): 14-19. Russian
28. Downes MJ, Brennan ML, Williams НС, Dean RS. Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS). BMJ Open. 2016; (6): e011458. doi: 10.1136/bmjopen-2016-011458.
29. RevMan. 5.3 User Guid. Computer program. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. Accessed: https://community.cochrane.org/sites/default/files/uploads/inline-files/RevMan_5.3_User_Guide.pdf.
30. Gasim GI, Hamdan HZ, Hamdan SZ, Adam I. Epidemiology of hepatitis B and hepatitis C virus infections among hemodialysis patients in Khartoum, Sudan. J Med Virol. 2012; 84(1): 52-55. doi: 10.1002/jmv.22256.
31. Carrilho FJ, Moraes CR, Pinho JR, Mello IM, Bertolini DA, Lemos MF, et al. Hepatitis В virus infection in Haemodialysis Centres from Santa Catarina State, Southern Brazil. Predictive risk factors for infection and molecular epidemiology. BMC Public Health. 2004. 4: 13. doi: 10.1186/1471-2458-4-13.
32. Alashek WA, McIntyre CW, Taal MW. Hepatitis В and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors. BMC Infect Dis. 2012; 20 (12): 265. doi: 10.1186/1471-2334-12-265.
33. Duong CM, Olszyna D, McLaws ML. Hepatitis В and C virus infections among patients with end stage renal disease in a low-resourced hemodialysis center in Vietnam: a cross-sectional study. BMC Public Health. 2015; 27 (15): 192. doi: 10.1186/ S12889-015-1532-9.
34. Lioussfi Z, Errami Z, Radoui A, Rhou H, Ezzaitouni F, Ouzeddoun N, et al. Viral hepatitis C and В among dialysis patients at the Rabat University Hospital: prevalence and risk factors. Saudi J Kidney Dis Transpl. 2014; 25 (3): 672-679.
35. Daglar D, Ergani A, Demirbakan H, Ozhak Baysan B, Ongflt G, Ko^ak H, et al. Investigation of hepatitis В and hepatitis C virus infections by serological and molecular methods in hemodialysis patients. Mikrobiyol Bui. 2014; 48 (1): 143-150. doi: 10.5578/mb.5619.
36. Cordeiro VM, Martins B, Teles SA, Martins RMB, Cruvinel KPS, Matos MAD, et al. Decline in hepatitis В and C prevalence among hemodialysis patients in Tocantins, Northern Brazil. Revista do Institute de Medicina Tropical de Sao Paulo. 2018; 60:e36. doi: 10.1590/S1678-9946201860036.
37. Souza KP, Luz JA, Teles SA, Carneiro MA, Oliveira LA, Gomes AS, et al. Hepatitis В and C in the hemodialysis unit of Tocantins, Brazil: serological and molecular profiles. Mem Inst Oswaldo Cruz. 2003; 98 (5): 599-603.
38. Ferreira RC, Teles SA, Dias MA, Tavares VR, Silva SA, Gomes SA, et al. Hepatitis В virus infection profile in hemodialysis patients in Central Brazil: prevalence, risk factors, and genotypes. Mem Inst Oswaldo Cruz. 2006; 101 (6): 689-692.
39. Busek SU, Baba EH, Tavares Filho HA, Pimenta L, Salomao A, Correa-Oliveira R, et al. Hepatitis C and hepatitis В virus infection in different hemodialysis units in Belo Horizonte, Minas Gerais, Brazil. Mem Inst Oswaldo Cruz. 2002; 97 (6): 775-778. doi: 10.1590/S0074-02762002000600003.
40. Chingayeva GN, Nugmanova AM, Alimzhanova EB, Kulkaeva MN, Dosym SM, Ismailova DB, et al. Viral hepatitis В in children's hemodialysis units of the Republic of Kazakhstan. Clinical Medicine of Kazakhstan. 2014; 1-1: 74-75. Russian
41. Zubkin ML. Vaccine-prophylaxis of hepatitis В in patients on hemodyalisis. Nephrology and dialysis. 2003; 5 (1): 24-32. Russian
42. А1 Hijazat М, Ajlouni YM. Hepatitis В infection among patients receiving chronic hemodialysis at the Royal Medical Services in Jordan. Saudi J Kidney Dis Transpl. 2008; 19 (2): 260-267.
43. Teles SA, Martins RM, Gomes SA, Gaspar AM, Araujo NM, Souza KP, et al. Hepatitis В virus transmission in Brazilian hemodialysis units: serological and molecular follow-up. J Med Virol. 2002. 68 (1). 41-49. doi: 10.1002/jmv.l0168.
44. Castro-Figueiredo JF, Moyses-Neto M, Gomes UA, Spalini-Ferraz A, Nardin-Batista ME, Coimbra-Gaspar AM, et al. Hepatitis B virus infection in hemodialysis units: clinical features, epidemiological markers and general control measures. Braz J Med Biol Res. 1986;19 (6): 735-742.
45. Alvarado-Esquivel C, Sablon E, Conde-Gonzalez CJ, Juarez-Figueroa L, Ruiz-Maya L, Aguilar-Benavides S. Molecular analysis of hepatitis B virus isolates in Mexico: predominant circulation of hepatitis В virus genotype H. World J Gastroenterol. 2006; 12 (40): 6540-6545. doi: 10.3748/wjg.vl2.i40.6540.
46. Lusida MI, Surayah, Sakugawa H, Nagano-Fujii M, Soetjipto, Mulyanto, et al. Genotype and subtype analyses of hepatitis B virus (HBV) and possible coinfection of HBV and hepatitis C virus (HCV) or hepatitis D virus (HDV) in blood donors, patients with chronic liver disease and patients on hemodialysis in Surabaya, Indonesia. Microbiol Immunol. 2003; 47 (12): 969-975.
47. Ramalingam S, Leung T, Cairns H. Sibley P, Smith M, Ijaz S, et al. Transmission of hepatitis В virus (genotype E) in a haemodialysis unit. J Clin Virol. 2007; 40 (2): 105-109. doi: 10.1016/j.jcv.2007.07.012.
48. De Castro L, Araujo NM, Sabino RR, Alvarenga F, Yoshida CF, Gomes SA. Nosocomial spread of hepatitis В virus in two hemodialysis units, investigated by restriction fragment length polymorphism analysis. Eur J Clin Microbiol Infect Dis. 2000; 19 (7): 531-537.
49. Besisik F, Karaca C, Akyuz F, Horosanli S, Onel D, Badur S, et al. Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection. J Hepatol. 2003; 38 (4): 506-510. doi: 10.1016/S0168-8278(02)00457-9.
50. MottaJS, Mello FC, Lago BV, Perez RM,Gomes SA, Figueiredo FF. Occult hepatitis В virus infection and lamivudine-resistant mutations in isolates from renal patients undergoing hemodialysis. J Gastroenterol Hepatol. 2010; 25 (1): 101-106. doi: 10.1111/j.l440-1746.2009.05972.x.
51. Wang C, Sun J, Zhu B, Larsen S, Yu R, Wu J, et al. Hepatitis B virus infection and related factors in hemodialysis patients in China - systematic review and meta-analysis. Ren Fail. 2010; 32 (10): 1255-1264. doi: 10.3109/0886022X.2010.517354.
52. Feng Y, Shi X. Immunogenicity, antibody persistence, and safety of the 60 pg hepatitis В vaccine in hemodialysis patients: a multicenter, randomized, double-blind, parallel-controlled trial. Expert Rev Vaccines. 2017; 16 (10); 1045-1052. doi: 10.1080/14760584.2017.1367667.
53. Asan A, Demirhan H, Sorkun HC, Ozkan S, Aydtn M, Akin D, et al. Factors affecting responsiveness to hepatitis В immunization in dialysis patients. Int Urol Nephrol. 2017; 49 (10): 1845-1850. doi: 10.1007/sll255-017-1616-9.
54. Cordova E, Miglia I, Festuccia F, Sarlo MG, Scornavacca G, Punzo G, et al. Hepatitis В vaccination in haemodialysis patients: an underestimated problem. Factors influencing immune responses in ten years of observation in an Italian haemodialysis centre and literature review. Ann Ig. 2017; 29 (1): 27-37. doi: 10.7416/ai.2017.2129.
55. Al Saran K, Sabry A, Al Halawany Z, Ismail M. Factors affecting response to hepatitis B vaccine among hemodialysis patients in a large Saudi Hemodialysis Center. Saudi J Kidney Dis Transpl. 2014; 25 (1): 185-191.
56. Kostinov MP, Tarasova AA. Vaccination of Children with Hemoblastosis. Epidemiology and Vaccinal Prevention. 2018; 17 (1): 74-75. Russian doi: 10.31631/2073-3046-2018-17-1-74-75.
57. Naushabayev АЕ, Abeuova BA, Chingayev GN, Nurbekova AA, Kabulbayev KA. Nephritic syndrome in children: morphological variants and treatment. Clinical Nephrology. 2012; (2): 60-63. Russian
58. Anding К, Gross Р, Rost JM, Allgaier D, Jacobs E. The influence of uraemia and haemodialysison neutrophil phagocytosisand antimicrobial killing. Nephrol Dial Transplant. 2003; 18 (10): 2067-2073. doi: 10.1093/ndt/gfg330.
59. Elhanan E, Boaz M, Schwartz I, Schwartz D, Chernin G, Soetendorp H, et al. A randomized, controlled clinical trial to evaluate the immunogenicity of a PreS/S hepatitis В vaccine Sci-B-Vac, as compared to Engerix B, among vaccine naive and vaccine non-responder dialysis patients. Clin Exp Nephrol. 2018; 22 (1): 151-158. doi: 10.1007/sl0157-017-1416-7.
60. Zitt E, Hafner-Giessauf H, Wimmer B, Herr A, Horn S, Friedl C, et al. Response to active hepatitis В vaccination and mortality in incident dialysis patients. Vaccine. 2017; 35 (5): 814-820. doi: 10.1016/j.vaccine.2016.12.032.
61. Grzegorzewska AE, Jodlowska E, Mostowska A, Jagodzinski P. Effect of interferon A3 gene polymorphisms, rs8099917 and rsl2979860, on response to hepatitis В virus vaccination and hepatitis В or C virus infections among hemodialysis patients. Pol Arch Med Wewn. 2015; 125 (12): 894-902. doi: 10.20452/pamw.3205.
62. Zitt E, Sprenger-Mahr H, Knoll F, Neyer U, Lhotta K. Vitamin D deficiency is associated with poor response to active hepatitis В immunisation in patients with chronic kidney disease. Vaccine. 2012; 30 (5): 931-935. doi: 10.1016/j.vaccine.2011.11.086.
63. Eleftheriadis T, Antoniadi G, Liakopoulos V, Stefanidis I, Galaktidou G. Inverse association of serum 25-hydroxyvitamin D with markers of inflammation and suppression of osteoclastic activity in hemodialysis patients. Iran J Kidney Dis. 2012; (6): 129-135.
64. Fabrizi F, Dixit V, Martin P, Messa P. Meta-analysis: the impact of diabetes mellitus on the immunological response to hepatitis В virusvaccine in dialysis patients. Aliment Pharmacol Ther. 2011; 33 (7): 815-821. doi: 10.1111/j.l365-2036.2011.04589.x.
65. Patel N, Assimon MM, Bruni E, McNutt LA, Mason DL. Incidence and clinical predictors of nonresponse to hepatitis B vaccination among patients receiving hemodialysis: importance of obesity. South Med J. 2015; 108 (9): 567-573. doi: 10.14423/SMJ.0000000000000343.
66. Asan A, Demirhan H, Sorkun HC, Ozkan S, Aydtn M, Akin D, et al. Factors affecting responsiveness to hepatitis В immunization in dialysis patients. Int Urol Nephrol. 2017; 49 (10): 1845-1850. doi: 10.1007/sll255-017-1616-9.
67. Fabrizi F, Dixit V, Martin Р, Jadoul М, Messa Р. Meta-analysis: the impact of nutritional status on the immune response to hepatitis В virus vaccine in chronic kidney disease. Dig Dis Sci. 2012; 57: 1366-1372. doi: 10.1007/sl0620-011-1987-l.
68. Ferreira TMB, Guimaraes TGS, Fontenele AMM, Salgado N Filho, Ferreira ASP, Costa АРМ. Does infection by the hepatitis C virus decrease the response of immunization against thehepatitis B virus in individuals undergoing dialysis? J Bras Nefrol. 2017; 39 (2): 141-145. doi: 10.5935/0101-2800.20170020.
69. Lin SY, Liu JH, Lin CC, Wang SM, Tsai CA, Chou CY, et al. Comparison of hepatitis B surface antibody decay rates after vaccination between hemodialysis and peritoneal dialysis patients. Vaccine. 2011; 29: 3738-3741. doi: 10.1016/j.vaccine.2011.03.049.
70. Akoglu H, Dede F, Piskinpasa S, Falay MY, Odabas AR. Impact of low- or high-flux haemodialysis and online haemodiafiltration on inflammatory markers and lipid profile in chronic haemodialysis patients. Blood Purif. 2013; 35 (4): 258264. doi: 10.1159/000348453.
71. Fabrizi F, Dixit V, Martin P, Messa P. Erythropoietin use and immunogenicity of hepatitis B virus vaccine in chronic kidney disease patients: a meta-analysis. Kidney Blood Press Res. 2012; 35 (6): 504-510. doi: 10.1159/000335956.
72. Fabrizi F, Dixit V, Messa P, Martin P. Hepatitis В virus vaccine in chronic kidney disease: improved immunogenicity by adjuvants? A meta-analysis of randomized trials. Vaccine. 2012; 30(13): 2295-2300. doi: 10.1016/j.vaccine.2012.01.064.
73. Abara WE, Qaseem A, Schillie S, McMahon BJ, Harris AM, High Value Care Task Force of the American College of Physicians and the Centers for Disease Control and Prevention. Hepatitis B Vaccination, Screening, and Linkage to Care: Best Practice Advice From the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2017; 167 (11): 794-804. doi: 10.7326/M17-1106
74. Fabrizi F, Tarantino A, Castelnovo C, Martin P, Messa P. Recombinant Hepatitis В Vaccine Adjuvanted With AS04 in Dialysis Patients: A Prospective Cohort Study. Kidney Blood Press Res. 2015; 40 (6): 584-592. doi: 10.1159/000368534.
Review
For citations:
Kvashnina D.V., Kovalishena O.V., Saperkin N.V. Risk factors of hepatitis B in patients on hemodialysis: a systematic review. Fundamental and Clinical Medicine. 2019;4(2):107-119. (In Russ.) https://doi.org/10.23946/2500-0764-2019-4-2-107-119
Views:
727
Email this article 